Media Center

GSK and Alfasigma announce agreement on worldwide rights for linerixibat

Alfasigma Secures Exclusive Rights from Innovative Molecules to Parenteral Adibelivir for Treatment of HSV Encephalitis, an Ultra-Rare Disease

Filgotinib Shows Positive Topline Results Across Full Spectrum of Axial Spondyloarthritis in OLINGUITO Phase 3 Study

Alfasigma Reports Record Growth in First-Ever Financial Results; €1.87 billion Revenue Setting the Stage for Future Growth

ALFASIGMA AT UEG WEEK (Vienna, 12 -15 OCTOBER 2024)

Alfasigma announces the Completion of Marketing Authorisation Transfer for Jyseleca® in the European Union